Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Long-Term Capital Lease Obligation : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Long-Term Capital Lease Obligation?

Clinuvel Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Clinuvel Pharmaceuticals's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($0.47 Mil) but then declined from Jun. 2023 ($0.47 Mil) to Dec. 2023 ($0.00 Mil).

Clinuvel Pharmaceuticals's annual Long-Term Capital Lease Obligation declined from Jun. 2021 ($0.80 Mil) to Jun. 2022 ($0.66 Mil) and declined from Jun. 2022 ($0.66 Mil) to Jun. 2023 ($0.47 Mil).

Clinuvel Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Long-Term Capital Lease Obligation Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.12

0.76

0.80

0.66

0.47

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	0.66	-	0.47	-

Clinuvel Pharmaceuticals (OTCPK:CLVLF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Clinuvel Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.